A suspicious area on a prostate MRI can be difficult to locate during a biopsy using ultrasound alone. Cognitive fusion biopsy helps urologists target these areas by interpreting MRI findings alongside real-time ultrasound images, without requiring specialised image-fusion software.
On this Page
What Is Cognitive Fusion Biopsy?
Cognitive fusion biopsy is a targeted prostate biopsy technique used to investigate areas that appear suspicious for cancer on magnetic resonance imaging (MRI). It combines information from a prior MRI scan with live ultrasound imaging to guide the biopsy needle to the suspected lesion.
Unlike software fusion biopsy, which uses computer technology to overlay MRI and ultrasound images, cognitive fusion relies on the clinician’s ability to interpret the images and mentally match the lesion’s location.
According to the National Institute for Health and Care Excellence (NICE), cognitive fusion is an established approach to MRI-informed prostate biopsy. Its effectiveness depends partly on the clinician’s imaging knowledge and targeting skills.
How Does Cognitive Fusion Biopsy Work?
The procedure generally involves four steps:
1. Prostate MRI: A multiparametric MRI scan identifies suspicious areas within the prostate. Radiologists assess these findings using systems such as PI-RADS, which classifies lesions according to their likelihood of being clinically significant cancer.
2. Image interpretation: The urologist reviews the MRI images and identifies the lesion’s position, size, and relationship to anatomical landmarks.
3. Ultrasound-guided targeting: During the biopsy, the clinician examines real-time ultrasound images and mentally correlates them with the MRI findings to estimate the lesion’s location.
4. Tissue sampling: The biopsy needle is directed towards the suspected area to collect tissue samples for pathological examination. Additional systematic samples may also be taken from other prostate regions.
The procedure can be performed using either a transrectal or transperineal approach. The appropriate route depends on the clinical situation and the treating team’s assessment.
Benefits of Cognitive Fusion Biopsy
No specialised fusion software required: The technique uses MRI interpretation and ultrasound guidance without requiring a dedicated software-fusion platform. This can make targeted biopsy more accessible to centres with suitable imaging equipment and trained clinicians.
Targeted tissue sampling: Instead of relying exclusively on systematic sampling, the clinician can direct biopsy needles towards suspicious MRI findings. This can help identify clinically significant prostate cancer that might otherwise be missed.
Compatible with different biopsy routes: Cognitive targeting can be performed through the rectum or perineum, allowing clinicians to select an approach appropriate for the patient.
Can be combined with systematic biopsy: Sampling the MRI-visible lesion alongside other prostate regions may improve diagnostic assessment. The American Urological Association (AUA) recommends obtaining at least two targeted cores from suspicious MRI lesions, with the precise sampling strategy determined by clinical factors.
Cognitive Fusion Biopsy vs Software Fusion Biopsy
Both techniques use MRI findings to guide prostate biopsy, but their targeting methods differ.
| Feature | Cognitive Fusion | Software Fusion |
| Image alignment | Clinician interprets and mentally matches images | Software overlays MRI and ultrasound images |
| Specialised fusion software | Not required | Required |
| Targeting method | Visual estimation | Computer-assisted registration |
| Operator expertise | Strong MRI interpretation and ultrasound skills are important | Imaging skills and familiarity with the fusion system are important |
| Main limitation | Target location can be difficult to estimate precisely | Registration errors and prostate deformation can affect targeting |
Software fusion provides a visual representation of the MRI target on ultrasound, but this does not automatically make it more accurate in every clinical situation.
A 2024 systematic review published by the National Institute for Health and Care Research found that software fusion might improve detection of clinically significant prostate cancer compared with cognitive fusion. However, the evidence was uncertain because of limitations in the underlying studies.
Limitations and Accuracy
Cognitive fusion biopsy relies heavily on the operator’s experience. Small lesions, difficult anatomical locations, prostate deformation between MRI and ultrasound, and unclear anatomical landmarks can make accurate targeting challenging.
A negative biopsy result also does not always exclude cancer. If MRI findings remain suspicious despite negative pathology, clinicians may consider further assessment, repeat imaging or another biopsy, depending on the patient’s overall risk.
Importantly, the European Association of Urology (EAU) recognises cognitive guidance, software fusion and direct MRI-guided biopsy as available methods for targeting MRI-visible lesions. Its review of comparative evidence does not establish clear overall superiority of one targeting technique across all clinical settings.
Conclusion
Cognitive fusion biopsy is an established method of MRI-targeted prostate sampling that uses the clinician’s interpretation of MRI and real-time ultrasound images. It avoids the need for specialised fusion software, but successful targeting depends on operator expertise and the visibility of the lesion.
For clinicians choosing a biopsy technique, the decision should consider MRI findings, patient-specific factors, available equipment, and local expertise.
Key Takeaways
- Cognitive fusion biopsy combines MRI findings with real-time ultrasound to target suspicious prostate lesions.
- It does not require specialised image-fusion software.
- Accuracy depends on the clinician’s experience and the lesion’s location.
- Clinicians can perform it using either a transperineal or transrectal approach.
- A negative result does not always rule out prostate cancer.
FAQs
1. What is cognitive fusion biopsy?
It is a targeted prostate biopsy technique that uses MRI findings and ultrasound imaging to guide needle placement.
2. Is cognitive fusion biopsy accurate?
It can detect clinically significant prostate cancer, but accuracy depends on lesion visibility, targeting skills, and other clinical factors.
3. Is cognitive fusion biopsy better than software fusion biopsy?
Neither is universally superior. Software fusion helps align images, while cognitive fusion relies on the clinician’s interpretation.
4. Can cognitive fusion biopsy miss prostate cancer?
Yes. If suspicion remains despite a negative result, further evaluation may be necessary.
5. Is cognitive fusion biopsy performed under local anaesthesia?
It can be performed under local anaesthesia, particularly through the transperineal route. The anaesthesia used depends on the procedure and clinical circumstances.